Journal
SCIENCE TRANSLATIONAL MEDICINE
Volume 4, Issue 120, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.3003728
Keywords
-
Categories
Funding
- Xcovery
- Conquer Cancer Foundation/American Society of Clinical Oncology
- Uniting Against Lung Cancer award
- Vanderbilt University School of Medicine Division of Hematology-Oncology
- Vanderbilt Specialized Program of Research Excellence in Lung Cancer grant [CA90949]
- Vanderbilt-Ingram Cancer Center Core grant [P30-CA68485]
Ask authors/readers for more resources
Mutated anaplastic lymphoma kinase (ALK) drives the development of multiple tumor types, and ALK tyrosine kinase inhibitors such as crizotinib have been validated as targeted therapeutics. Unfortunately, as with other oncogene-driven tumors, therapeutic resistance invariably develops. In Science Translational Medicine, two recent studies provide new insight into mechanisms of resistance to ALK tyrosine kinase inhibitors and possible strategies to overcome this resistance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
